Whitehead Institute for Biomedical Research ning to be understood, but at least include
exposure of Howard Hughes Medical Institute the “fusion” peptide at the amino terminus of …

Evolutionary modelling studies indicate less than a century has passed since the most
recent common ancestor of the HIV-1 pandemic strains and, in that time frame, an …

The development of an effective human immunodeficiency virus type 1 (HIV-1) vaccine is
likely to depend on knowledge of circulating variants of genes other than the commonly …

We propose that retroviruses exploit a cell-encoded pathway of intercellular vesicle traffic,
exosome exchange, for both the biogenesis of retroviral particles and a low-efficiency but …

The few antibodies that can potently neutralize human immunodeficiency virus type 1 (HIV-
1) recognize the limited number of envelope glycoprotein epitopes exposed on infectious …

ABSTRACT 2G12 is a broadly neutralizing human monoclonal antibody against human
immunodeficiency virus type-1 (HIV-1) that has previously been shown to bind to a …

The cellular immune response to the human immunodeficiency virus, mediated by T
lymphocytes, seems strong but fails to control the infection completely. In most virus …

Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …

The envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) function as a
trimer composed of three gp120 exterior glycoproteins and three gp41 transmembrane …

The third variable region, V3, of the gp120 surface envelope glycoprotein is an
approximately 35-residue-long, frequently glycosylated, highly variable, disulfide-bonded …